Management weighed a new Mexican tax law's cash flow impact on expansion.

Pfizer lifts guidance as newer drugs grow, even as COVID sales keep falling.

Oct 25, 2026 •By Jonathan PoncianoEro Copper's 2027 Outlook: Leverage Down From 2.6x to 0.8x With a 24-Year Growth Project Waiting in the Wings

Arkansas bromine timeline holds while international sales hit a decade high.

Record home sales lifted results, but higher refinancing rates cloud the outlook.

Power margins climbed, but heavy capex and oil hedges pressured cash flow.

Acquisition and a longer hedge book shape the quarter's outlook.

Personalization beat its target while the order book runs deep into 2028.

AI adoption fueled growth, and full-year guidance moved higher.

Refining margins surged while the company sold two refineries and boosted payouts.

Biologics demand held firm while GLP-1 volumes shape the 2027 outlook.

Data center demand and a 65% revenue jump lifted Eaton's outlook this quarter.

Pricing discipline cut sand volumes as its power build-out accelerated.

A $995 million defense contract and a CEO retirement shape this quarter.

Software margins hit a record while AI tools are cutting internal workloads sharply.

Hardie transition and affordability pressures shape the fourth-quarter outlook.

Search losses are forcing a pivot to nonsession revenue and leaner staffing.

Life science bets and re-leasing lifted AFFO per share 7% sequentially

Acquisitions and a new capital plan shape the latest update.

Fee-related earnings hit a record as capital solutions and origination activity climbed.

Guidance was raised again, but midweek demand still trails 2019 levels.

Asset sales and a Colorado acquisition shaped results despite weak Alberta power prices.

Rising input costs and a pivot to quarterly pricing shape the outlook.

Memory cost pressures are testing margins even as sales hit a record.

Record margins held up despite softer CPG demand, and guidance moved higher.

Management says the fund seeding phase is complete and the focus has shifted.

Devon Eagle Ford deal reshapes Crescent's debt reduction plans.

Penn District leasing and a $204 million signed pipeline shape its outlook.

Cash runway now stretches into 2029 as clinical programs advance.

Dividend hike and Stop Loss pricing shape a quarter focused on margin recovery.

Revenue rose 8.9% and guidance was raised again, though margins slipped.

Asking rents are up about 3% as concessions burn off and renovation turns speed up.

Raised guidance and rate wins lifted results, but a possible Fed hike looms.

Management shifts toward first lien loans as yellow-rated assets edge higher.

Divestiture progress and cash generation drive a stronger outlook